AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1550275
Drug: Supplementary dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplementary dose of 10 mg propofol (for treatment failures in placebo group)
Trial: 3897722
Drug: 330 mg
RxNorm normalized name: urea 330 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 330 mg of acetylsalicylic acid (aspirin) plus 75 mg of dipyridamole three times daily
Trial: 22858559
Drug: Concurrent ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Concurrent ipilimumab
Trial: 29303446
Drug: Concurrent ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Concurrent ipilimumab with SRS dose ≥ 20 Gy
Trial: 25189328
Drug: Educational programme
RxNorm normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational programme based on the Health Belief Model (HBM), consisting of four 1-hour sessions twice per week
Trial: 19147137
Drug: PID patients
RxNorm normalized name: PID
DrugBank: Phenindione (DB00498)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PID patients with myeloperoxidase G/A alleles
Trial: 19147137
Drug: PID patients
RxNorm normalized name: PID
DrugBank: Phenindione (DB00498)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PID patients with G/G homozygous alleles
Trial: 11287776
Drug: Pyridoxine 100
RxNorm normalized name: pyridoxine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridoxine 100 mg/day
Trial: 18476391
Drug: Ferrous sulphate
RxNorm normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulphate tablet 100 mg (Control)
Trial: 15650846
Drug: Ziprasidone (IM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone (IM up to 3 days, then oral 40-80 mg, b.i.d.)
Trial: 15650846
Drug: Haloperidol (IM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (IM up to 3 days, then oral 5-20 mg/day)
Trial: 7552502
Drug: IDUs enrolled
RxNorm normalized name: IdU
DrugBank: Idoxuridine (DB00249)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IDUs enrolled in the HIV vaccine trial
Trial: 2349198
Drug: Nebulised fenoterol
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised fenoterol (5 mg)
Trial: 2349198
Drug: Nebulised terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised terbutaline (5 mg)
Trial: 1757610
Drug: 0.05% betamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% betamethasone dipropionate cream
Trial: 387495
Drug: 0.025% fluocinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.025% fluocinolone acetonide cream
Trial: 16960411
Drug: Carvedilol therapy
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol therapy (6.25 mg/day uptitrated to 23.9 +/- 13.9 mg)
Trial: 12670065
Drug: At-home treatment
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At-home treatment with 10% carbamide peroxide
Trial: 12670065
Drug: In-office treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-office treatment with 35% hydrogen peroxide
Trial: 12670065
Drug: At-home treatment
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At-home treatment
Trial: 12670065
Drug: In-office treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-office treatment
Trial: 1555086
Drug: alpha‐ketoisocaproate (17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha‐ketoisocaproate (17 g day‐1)
Trial: 1555086
Drug: branched chain
RxNorm normalized name: Branched Chain Amino Acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: branched chain solution (3.3 g nitrogen day‐1)
Trial: 1555086
Drug: balanced amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: balanced amino acid solution (no further supplements)
Trial: 31272834
Drug: Mokuboito plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mokuboito plus standard therapy
Trial: 26301603
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of antihypertensive treatment (n=199)
Trial: 26301603
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of antihypertensive treatment (n=186)
Trial: 26301603
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of antihypertensive treatment
Trial: 23839180
Drug: Duac® Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duac® Gel (BPO 5%‐clindamycin phosphate 1.2%)
Trial: 23839180
Drug: Acanya® Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acanya® Gel (BPO 2.5%‐clindamycin phosphate 1.2%)
Trial: 23839180
Drug: Aczone® Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aczone® Gel (dapsone 5%)
Trial: 23839180
Drug: Epiduo® Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epiduo® Gel (BPO 2.5%‐adapalene 0.1%)
Trial: 16440121
Drug: Nebulized terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized terbutaline plus intravenous betamethasone
Trial: 15571785
Drug: Family-focused psychoeducational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-focused psychoeducational treatment for bipolar adolescents (FFT-A) combined with mood stabilizing medications
Trial: 11810324
Drug: Harpagophytum extract
RxNorm normalized name: Harpagophytum procumbens whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Harpagophytum extract LI 174 (Rivoltan(R)) 2x480 mg/day for 4 weeks
Trial: 29311137
Drug: AZD7325 (4‐amino‐8‐(2‐fluoro‐6‐methoxyphenyl)‐N‐propylcinnoline‐3‐carboxamide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD7325 (4‐amino‐8‐(2‐fluoro‐6‐methoxyphenyl)‐N‐propylcinnoline‐3‐carboxamide) administered orally, repeated doses over a period not specified.
Trial: 25342205
Drug: DEX 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX 1.0 µg/kg 5 min before propofol injection (group VII)
Trial: 22145513
Drug: Ramtace 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramtace 10 mg (test product)
Trial: 10981566
Drug: 0.5 microg/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 microg/ml sufentanil
Trial: 10981566
Drug: 0.75 microg/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 microg/ml sufentanil
Trial: 10981566
Drug: 1 microg/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 microg/ml sufentanil
Trial: 9024262
Drug: Ovine CRH
RxNorm normalized name: Ovine CRH
DrugBank: Corticorelin ovine triflutate (DB09067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovine CRH (oCRH) injection during desmopressin (DP) infusion
Trial: 9024262
Drug: Ovine CRH
RxNorm normalized name: Ovine CRH
DrugBank: Corticorelin ovine triflutate (DB09067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovine CRH (oCRH) injection during saline (SAL) infusion
Trial: 9024262
Drug: Desmopressin (DP)
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Desmopressin (DP) infusion plus SAL injection
Trial: 9024262
Drug: SAL injection
RxNorm normalized name: Mepivacaine Hydrochloride 30 mg in 1 mL SUBMUCOSAL INJECTION, SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAL injection during SAL infusion
Trial: 8453023
Drug: Dolasetron administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolasetron administered orally at doses ranging from 50 to 400 mg (mesylate monohydrate)
Trial: 16432050
Drug: Hydrochlorothiazide 25
RxNorm normalized name: hydrochlorothiazide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 25 mg/day
Trial: 8068472
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg/day
Trial: 3142400
Drug: Both drugs
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both drugs (at D 90)
Trial: 29320595
Drug: 1060 nm
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1060 nm laser treatment
Trial: 23761964
Drug: 0.15% GCV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15% GCV in situ ophthalmic gel
Trial: 23761964
Drug: 0.15% GCV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15% GCV ophthalmic gel (control)
Trial: 17058824
Drug: Shexiang Baoxin
RxNorm normalized name: CAMPHOR (NATURAL) 30.53 mg / MENTHOL 40.71 mg / METHYL SALICYLATE 25.95 mg TOPICAL PLASTER [SheXiang ZhuangGu Gao]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shexiang Baoxin Pill (SBP) plus routine treatment
Trial: 10804656
Drug: Different treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different treatments evaluated in randomized trials
Trial: 2107242
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate (SCG) nebulizer solution 1% administered three to four times daily for 8 weeks
Trial: 19582579
Drug: Open-label lansoprazole
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open-label lansoprazole therapy (dose-titrated)
Trial: 17884925
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline infusion into biceps brachii
Trial: 10323377
Drug: 4-6 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-6 mg/day lacidipine
Trial: 10323377
Drug: 10-20 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-20 mg/day lisinopril
Trial: 6271814
Drug: THC, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC, 5 mg
Trial: 6271814
Drug: Prochlorperazine (PCPZ),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prochlorperazine (PCPZ), 10 mg
Trial: 6271814
Drug: THC, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC, 10 mg
Trial: 6271814
Drug: THC, 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC, 15 mg
Trial: 31283756
Drug: Dofetilide, Moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dofetilide, Moxifloxacin (potassium channel blockers)
Trial: 31283756
Drug: Mexiletine, Lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexiletine, Lidocaine (sodium or calcium channel blockers)
Trial: 31283756
Drug: Ranolazine (multichannel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranolazine (multichannel blocking drug)
Trial: 31283756
Drug: Dofetilide +
RxNorm normalized name: Dofetilide
DrugBank: Dofetilide (DB00204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dofetilide + Mexiletine, Dofetilide + Lidocaine (drug combinations)
Trial: 31283756
Drug: Tr40c (parameter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tr40c (parameter for differentiating drugs)
Trial: 31283756
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Tr10c to Tr100c in logistic regression model
Trial: 25646201
Drug: 20‐mL/kg isotonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20‐mL/kg isotonic saline bolus
Trial: 21429094
Drug: Patch users
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch users
Trial: 21429094
Drug: Commercially available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available patches
Trial: 21429094
Drug: Non-patch users
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-patch users
Trial: 20110012
Drug: Once-daily extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily extended-release (ER) pramipexole 0.75 mg
Trial: 20110012
Drug: Single-dose ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose ER pramipexole 0.375 mg (fasted state)
Trial: 20110012
Drug: Single-dose ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose ER pramipexole 0.375 mg (fed state)
Trial: 20110012
Drug: Steady-state ER
RxNorm normalized name: CLOZAPINE (GOLDEN STATE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steady-state ER pramipexole 0.375 to 4.5 mg (fasted state)
Trial: 20110012
Drug: Steady-state ER
RxNorm normalized name: CLOZAPINE (GOLDEN STATE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steady-state ER pramipexole 4.5 mg
Trial: 17827952
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of infliximab with immunosuppressives at onset
Trial: 15176536
Drug: Oral refeeding
RxNorm normalized name: Defend II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral refeeding
Trial: 9601682
Drug: 5‐HT2A receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐HT2A receptor promoter polymorphism ‐1438G/A in patients with mood disorders
Trial: 2684554
Drug: CPAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP treatment after 1 night
Trial: 2684554
Drug: CPAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP treatment after 14 nights
Trial: 2684554
Drug: CPAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP treatment after 42 nights
Trial: 1102646
Drug: Antiheart antibody
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiheart antibody (AHA) in high titer
Trial: 1102646
Drug: Rise in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rise in titer to viral agents
Trial: 30168415
Drug: Namilumab 300
RxNorm normalized name: Namilumab
DrugBank: Namilumab (DB13037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Namilumab 300 mg
Trial: 28274253
Drug: Namilumab (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Namilumab (150 and 300 mg combined)
Trial: 25567115
Drug: Anrukinzumab 200
RxNorm normalized name: Anrukinzumab
DrugBank: Anrukinzumab (DB12294)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anrukinzumab 200 mg
Trial: 25567115
Drug: Anrukinzumab 400
RxNorm normalized name: Anrukinzumab
DrugBank: Anrukinzumab (DB12294)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anrukinzumab 400 mg
Trial: 25567115
Drug: Anrukinzumab 600
RxNorm normalized name: Anrukinzumab
DrugBank: Anrukinzumab (DB12294)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anrukinzumab 600 mg
Trial: 25567115
Drug: Anrukinzumab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anrukinzumab (all doses)
Trial: 16469404
Drug: Corticosteroids (prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids (prednisolone 30 mg daily)
Trial: 14506496
Drug: 2 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/day of fish oil (containing approximately 450 mg eicosapentaenoic acid and 350 mg docosahexaenoic acid)
Trial: 10684911
Drug: Metronidazole (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (two 2-g doses)
Trial: 26733410
Drug: SkQ1 1.55
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SkQ1 1.55 µg/mL
Trial: 26733410
Drug: SkQ1 0.155
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SkQ1 0.155 µg/mL
Trial: 26733410
Drug: 0.0 µg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0 µg/mL (placebo)
Trial: 24378998
Drug: Barostim therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barostim therapy
Trial: 22503105
Drug: Tacrolimus (TAC)
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus (TAC) therapy with prednisone, initiated at 0.05 mg/kg/d, adjusted to maintain a trough blood level of 5 to 10 ng/mL for 1 year.
Trial: 22503105
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) pulse cyclophosphamide (CTX) therapy with prednisone, initiated at 1 g/1.73 m(2) for a total dosage of 10 g/1.73 m(2) over 1 year.
Trial: 20489031
Drug: Dalcetrapib (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalcetrapib (900 mg) plus pravastatin
Trial: 20489031
Drug: Dalcetrapib (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalcetrapib (900 mg) plus rosuvastatin
Trial: 20489031
Drug: Dalcetrapib (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalcetrapib (900 mg) plus simvastatin
Trial: 20489031
Drug: Dalcetrapib (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalcetrapib (900 mg)
Trial: 16126119
Drug: metformin+RSG 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin+RSG 4 mg b.i.d.
Trial: 16126119
Drug: metformin+placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin+placebo
Trial: 12198218
Drug: Post-haemodialysis administration
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-haemodialysis administration of vancomycin 15 mg/kg
Trial: 9445320
Drug: rpro-UK (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rpro-UK (6 mg)
Trial: 3981625
Drug: Diazepam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (10 mg orally)
Trial: 26918564
Drug: 28-day buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28-day buprenorphine taper
Trial: 26918564
Drug: 56-day buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 56-day buprenorphine taper
Trial: 23421088
Drug: Emdogain treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emdogain treatment
Trial: 15640389
Drug: REX-albuterol treatment
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REX-albuterol treatment
Trial: 9826114
Drug: (+)-UH232, single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (+)-UH232, single doses of 80 to 180 mg
Trial: 71969
Drug: Flurbiprofen (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen (150 mg to 200 mg daily)
Trial: 71969
Drug: Indomethacin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (75 mg to 100 mg daily)
Trial: 30053042
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of AL-794
Trial: 30053042
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of AL-794
Trial: 23666599
Drug: RAHelp online
RxNorm normalized name: FILTER,SUCTION,INLINE #FHBF200S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAHelp online intervention with weekly telephone support
Trial: 21858614
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL of 0.75% ropivacaine (Group 5)
Trial: 21858614
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of 0.75% ropivacaine (Group 10)
Trial: 17302069
Drug: Refined Xuefu
RxNorm normalized name: refined almond oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refined Xuefu Capsule (RXC) for 3 months
Trial: 17302069
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Warfarin only)
Trial: 17302069
Drug: Refined Xuefu
RxNorm normalized name: refined almond oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refined Xuefu Capsule (RXC)
Trial: 15472166
Drug: Metformin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin administration (850 mg twice daily for 6 months)
Trial: 9105740
Drug: Endoventricular streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoventricular streptokinase infusion (20,000 U/day for 96 hours)
Trial: 3102167
Drug: Mupirocin ointment
RxNorm normalized name: Mupirocin Ointment
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mupirocin ointment applied 3-times daily for 4 to 10 days
Trial: 3102167
Drug: Erythromycin (oral)
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin (oral) in normal dosage for skin infections
Trial: 3102167
Drug: Flucloxacillin (oral)
RxNorm normalized name: cloxacillin Oral Capsule
DrugBank: Flucloxacillin (DB00301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flucloxacillin (oral) in normal dosage for skin infections
Trial: 25956171
Drug: Five-drug ART
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-drug ART (tenofovir+emtricitabine+efavirenz+raltegravir+maraviroc, n=18)
Trial: 25956171
Drug: Three-drug ART
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-drug ART (tenofovir+emtricitabine+efavirenz, n=18)
Trial: 21375852
Drug: Hyaluronate-iodine soaked
RxNorm normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronate-iodine soaked gauze applied to wounds either daily or every other day depending on the amount of wound exudate.
Trial: 17302372
Drug: Indomethacin (INDO)
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin (INDO) at a dosage of 1 mg/kg body weight, administered orally to CCoV-infected dogs.